Information for Authors:

Types of papers: The Journal of Medical Toxicology publishes original articles, illustrative cases, review articles, and other special features. Please note that JMT only accepts manuscripts written in proper English. For details of the types of paper we publish, see below.

Manuscript Submission: Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions: Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission: Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.

Title page: The title page should include:

• Sources of funding for project. • Conflict delineations • Previous presentation of data at meetings or in abstract form • Word count of manuscript, not counting title page or abstract • Three to five “key words” acceptable for National Library of Medicine indexing • The name(s) of the author(s) • A concise and informative title • The affiliation(s) and address(es) of the author(s) • The e-mail address, telephone and fax numbers of the corresponding author

Abstract: All submitted manuscripts, with the exception of submissions to The Poison Pen, should be accompanied by an abstract limited to 250 words. The abstract should be structured using the subheadings: Introduction, Methods, Results, and Conclusions (for original research); Introduction, Case Report(s), Discussion (for descriptive reports); or Introduction, Discussion, Conclusions (for reviews). References should not be cited in the abstract. Use of abbreviations and acronyms should be limited. Keywords: Please provide 4 to 6 keywords which can be used for indexing purposes.

Text Formatting: Manuscripts should be submitted in Word.

• Use a normal, plain font (e.g., 10-point Times Roman) for text. • Use italics for emphasis. • Use the automatic page numbering function to number the pages. • Do not use field functions. • Use tab stops or other commands for indents, not the space bar. • Use the table function, not spreadsheets, to make tables. • Use the equation editor or MathType for equations. • Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).

Manuscripts with mathematical content can also be submitted in LaTeX.

• LaTeX macro package (zip, 182 kB)

Headings: Please use no more than three levels of displayed headings.

Abbreviations: Abbreviations should be defined at first mention and used consistently thereafter.

Footnotes: Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables. Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols. Always use footnotes instead of endnotes.

Acknowledgments: Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full.

References:

Citation:

Reference citations in the text should be identified by numbers in square brackets. Some examples: 1. Negotiation research spans many disciplines [3]. 2. This result was later contradicted by Becker and Seligman [5]. 3. This effect has been widely studied [1-3, 7].

Reference List:

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.

The entries in the list should be numbered consecutively.

• Journal article o Redmond AD (1986) Central nervous system depression and high blood ethanol levels.

Lancet 327(8484):805 • Article by DOI

o Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med 2000; doi:10.1007/s001090000086

• Book o Finnell JT, McMicken DB (2009) In: Marx J, Hockberger R, Walls R, Adams JG et al (eds)

Rosen’s emergency medicine: concepts and clinical practice, 7th edn. Mosby/Elsevier, Philadelphia, p 2372

• Book chapter o Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH,

Danielli JF, Jeon KW, editors. International review of cytology. London: Academic; 1980. pp. 251–306.

• Online document o Doe J. Title of subordinate document. In: The dictionary of substances and their effects.

Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999.

Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see

• http://www.issn.org/2-22661-LTWA-online.php

Tables: • All tables are to be numbered using Arabic numerals. • Tables should always be cited in text in consecutive numerical order. • For each table, please supply a table caption (title) explaining the components of the table. • Identify any previously published material by giving the original source in the form of a reference

at the end of the table caption. • Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for

significance values and other statistical data) and included beneath the table body.

Artwork and Illustrations: For the best quality final product, it is highly recommended that you submit all of your artwork – photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the highest standards with the greatest accuracy to detail. The published work will directly reflect the quality of the artwork provided.

Electronic Figure Submission:

• Supply all figures electronically. • Indicate what graphics program was used to create the artwork. • For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MS Office

files are also acceptable. • Vector graphics containing fonts must have the fonts embedded in the files. • Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.

Line Art:

• Definition: Black and white graphic with no shading. • Do not use faint lines and/or lettering and check that all lines and lettering within the figures are

legible at final size. • All lines should be at least 0.1 mm (0.3 pt) wide. • Scanned line drawings and line drawings in bitmap format should have a minimum resolution of

1200 dpi. • Vector graphics containing fonts must have the fonts embedded in the files.

Halftone Art:

• Definition: Photographs, drawings, or paintings with fine shading, etc. • If any magnification is used in the photographs, indicate this by using scale bars within the

figures themselves. • Halftones should have a minimum resolution of 300 dpi.

Combination Art:

• Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.

• Combination artwork should have a minimum resolution of 600 dpi.

Color Art:

• Color art is free of charge for online publication. • If black and white will be shown in the print version, make sure that the main information will still

be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.

• If the figures will be printed in black and white, do not refer to color in the captions. • Color illustrations should be submitted as RGB (8 bits per channel).

Figure Lettering:

• To add lettering, it is best to use Helvetica or Arial (sans serif fonts). • Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–

12 pt). • Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an

axis and 20-pt type for the axis label. • Avoid effects such as shading, outline letters, etc. • Do not include titles or captions within your illustrations.

Figure Numbering:

• All figures are to be numbered using Arabic numerals. • Figures should always be cited in text in consecutive numerical order. • Figure parts should be denoted by lowercase letters (a, b, c, etc.). • If an appendix appears in your article and it contains one or more figures, continue the

consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.

Figure Captions:

• Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.

• Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.

• No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.

• Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.

• Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Figure Placement and Size:

• When preparing your figures, size figures to fit in the column width. • For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not

higher than 234 mm. • For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher

than 198 mm.

Permissions: If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Accessibility: In order to give people of all abilities and disabilities access to the content of your figures, please make sure that:

• All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)

• Patterns are used instead of or in addition to colors for conveying information (color-blind users would then be able to distinguish the visual elements)

• Any figure lettering has a contrast ratio of at least 4.5:1 Electronic Supplementary Material: Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form.

Submission:

• Supply all supplementary material in standard file formats. • Please include in each file the following information: article title, journal name, author names;

affiliation and e-mail address of the corresponding author. • To accommodate user downloads, please keep in mind that larger-sized files may require very

long download times and that some users may experience other problems during downloading.

Audio, Video, and Animations:

• Always use MPEG-1 (.mpg) format.

Text and Presentations:

• Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability. • A collection of figures may also be combined in a PDF file.

Spreadsheets:

• Spreadsheets should be converted to PDF if no interaction with the data is intended. • If the readers should be encouraged to make their own calculations, spreadsheets should be

submitted as .xls files (MS Excel).

Specialized Formats:

• Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

Collecting Multiple Files:

• It is possible to collect multiple files in a .zip or .gz file.

Numbering:

• If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.

• Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.

• Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.

Captions:

• For each supplementary material, please supply a concise caption describing the content of the file.

Processing of supplementary files:

• Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.

Accessibility: In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that

• The manuscript contains a descriptive caption for each supplementary material • Video files do not contain anything that flashes more than three times per second (so that users

prone to seizures caused by such effects are not put at risk)

After Acceptance: Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice, offprints, or printing of figures in color. Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.

Open Choice: In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink.

• Springer Open Choice

Copyright transfer: Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws. Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.

Offprints: Offprints can be ordered by the corresponding author.

Color illustrations: Online publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a contribution towards the extra costs.

Proof reading: The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor. After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online First: The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers. Scientific Style: Generic names of drugs and pesticides are preferred; if trade names are used, the generic name should be given at first mention. Integrity of Research and Reporting: Uniform Requirements for Manuscripts: “Preparing a Manuscript for Submission to Biomedical Journals” and “Authorship and Contributorship” accessible at http://www.icmje.org/urm_main.html. Although all manuscripts, except for selected editorial features, are subject to peer review, the responsibility for the accuracy and legitimacy of the scientific content of the manuscripts rests with the authors. It is also the responsibility of the authors to notify the editor in writing of all potentially perceived conflicts of interest, financial or otherwise (see also Conflicts of Interest below) Protection of Human Subjects: It is the authors’ responsibilities to ensure that all research protocols and manuscripts, including case reports, have been properly reviewed for adequate protection of human subjects as required by the authors’ institution(s). Such protections, as relevant, should be described in the Methods of the manuscript. All manuscripts must by compliant with existing standards for protection of protected health information (e,g., HIPAA). Protection of Animals in Research: It is the authors’ responsibility to ensure that all research manuscripts involving animal experimentation have followed appropriate procedures. When reporting experiments on animals, authors should indicate that they followed institutional and/or national guidelines for the care and use of laboratory animals. Such statements should be included in the Methods section. Conflicts of Interest: The Journal expects all authors to disclose all relevant financial relationships with all companies, organizations, or individuals regarding products discussed in a manuscript. Every author is expected to disclose individually each real or perceived potential conflicts. All authors must complete the Uniform Disclosure available at www.icmje.org/coi_disclosure.pdf ). Conflict of Interest Disclosure: When authors submit a manuscript, they are responsible for disclosing all financial and personal relationships that might bias their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. Each author must indicate whether or not they have a financial relationship with the organization that sponsored the research. For each source of funds, both the research funder and the grant number should be given.

Potential conflicts of interest exist when an author is related to a for-profit company or institution in any of the following ways:

1. Employment 2. Consultancies in the last 3 years (please list) 3. Honoraria in the last 3 years (please list) 4. Stock ownership/ options other than mutual funds (current; please list) 5. Expert testimony in the last 3 years (please list) 6. Grants received in the last 3 years (please list) 7. Grants pending (please list) 8. Patents received 9. Patents pending 10. Royalties (describe) 11. Other relationships (please specify)

Conflict of interest statements should be present on every manuscript before the References section. The statement should mention each author separately by name. Recommended wording is as follows: Author X declares that he has no conflict of interest. Author Y has received research grants from Drug Company A. Author Z has received a speaker honorarium from Drug Company B and owns stock in Drug Company C. If multiple authors declare no conflict, this can be done in one sentence: Author X, Author Y and Author Z declare that they have no conflict of interest. Follow the below link for Springer's Conflict of Interest Statement:

• http://www.springer.com/authors?SGWID=0-111-6-791531-0

Informed Consent: For studies with human subjects, please include the following statement before the References section:

• 'All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.'

Any experimental protocol must be approved, and owing to US regulations (the recent Health Insurance Portability and Accountability Act - HIPAA) even studies without any experimental protocol merely reporting patients or patient material require approval; these regulations require review for any studies involving patient identity, including retrospective chart, radiographic reviews, or removed tissues or materials. If any identifying information about patients is included in the article, the following sentence should also be included:

• 'Additional informed consent was obtained from all patients for which identifying information is included in this article.'

Follow the below link for Springer's Informed Consent Statement: • http://www.springer.com/authors?SGWID=0-111-6-608209-0

Animal Studies: For studies with animals, include the following sentence in the manuscript before the References section:

• 'All institutional and national guidelines for the care and use of laboratory animals were followed.' If the authors did not carry out animal and/or human studies as part of their article they must include the following statement in the manuscript before the References section:

• 'No animal or human studies were carried out by the authors for this article' The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements. Follow the below link for Springer's Animal and Human Rights Statement

• http://www.springer.com/authors?SGWID=0-111-6-608309-0

Does Springer Provide English Language Support? Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and formal style. This may not be sufficient if English is not your native language and substantial editing would be required. In that case, you may want to have your manuscript edited by a native speaker prior to submission. A clear and concise language will help editors and reviewers concentrate on the scientific content of your paper and thus smooth the peer review process. The following editing service provides language editing for scientific articles in all areas Springer publishes in. Use of an editing service is neither a requirement nor a guarantee of acceptance for publication. Please contact the editing service directly to make arrangements for editing and payment.

For Authors from China: 文章在投稿前进行专业的语言润色将对作者的投稿进程有所帮助。作者可自愿选择使用 Springer推荐的编辑服务，使用与否并不作为判断文章是否被录用的依据。提高文章的语言质量将有助于审稿人理解文章的内容，通过对学术内容的判断来决定文章的取舍，而不会因为语言问题导致直接退稿。作者需自行联系Springer推荐的编辑服务公司，协商编辑事宜。

• 理文编辑

For Authors from Japan: ジャーナルに論文を投稿する前に、ネイティブ・スピーカーによる英文校閲を希望されている方には、Edanz社をご紹介しています。サービス内容、料金および申込方法など、日本語による詳しい説明はエダンズグループジャパン株式会社の下記サイトをご覧ください。

• エダンズ グループ ジャパン

For Authors from Korea: 영어 논문 투고에 앞서 원어민에게 영문 교정을 받고자 하시는 분들께 Edanz 회사를 소개해 드립니다. 서비스 내용, 가격 및 신청 방법 등에 대한 자세한 사항은 저희 Edanz Editing Global 웹사이트를 참조해 주시면 감사하겠습니다.

Toxicology Observations:

1. The title should reveal the unusual aspect of the case. 2. The case should describe a unique or rare clinical finding or toxicological disease process of

interest and value to JMT readers. Cases describing unique pharmacokinetic data, analytical methods, diagnostic tests, or therapeutic modalities are also appropriate.

3. The introduction should provide a brief background on the topic and explain why the report is of value.

4. The case must be well documented and include all relevant clinical information. Most important, there should be laboratory confirmation of the agent ingested whenever possible, with an attempt to exclude other possible causes of the finding or disease process. Credible corroborative evidence should be presented in all cases. Reports relying solely on patient history or proximity to a toxin (e.g., presence of pill bottles) are not generally acceptable. For fatalities, postmortem examination and forensic toxicology results are highly desirable.

5. The discussion should focus on the unique aspect of the case being presented. Plausibility should be addressed, with potential mechanisms for the clinical finding or drug effect provided. If the finding or condition is not consistent with what we already know about the toxicological agent involved, this should also be addressed in the discussion.

6. Include a concise review of other relevant medical literature or similar case reports in the discussion. This should not be a review of all available literature.

7. Address limitations of the report, including other possible causes of the finding or condition, if they exist.

8. Toxicology Observations should be approximately 1500 words with 10 references and no more than 3 figures or tables.

For an expanded discussion of a well written toxicology case report, please see "Ruha AM: The Case Report: A Tool for the Toxicologist. Journal of Medical Toxicology 2009; 5:1-2. Toxicology Reviews: Review articles may be solicited by the Review Editor, but uncommissioned material is encouraged. Please contact the Section Editor, Michelle Ruha (michelle.ruha@bannerhealth.com), before writing a review for the Journal to ensure that the topic is appropriate for the Journal and does not conflict with another pending or published review. Focused and comprehensive reviews are expected to be critical assessments of literature and data sources pertaining to clinical topics, emphasizing factors such as etiology, diagnosis, prognosis, therapy, or prevention. Systematic and narrative reviews are accepted, although a systematic approach should be used whenever possible. All articles or data sources should be searched for and selected systematically for inclusion and critically evaluated. The specific type of study or analysis, population, intervention, exposure, tests, or outcomes should be described for each article or data source. When creating a title, include words that indicate to the reader this is a review. (Ex: “Clearing the Air: A Review of the Effects of Particulate Matter Air Pollution on Human Health”). Review articles that address a specific clinical

question should include a short case vignette or paragraph (no more than 100 words) describing the clinical question in the Introduction. The search and selection process of reviewed material must be described in the manuscript for all review types in the Methods section of the article. At a minimum, this should include databases and years searched, and key words used, as well as inclusion and exclusion criteria. Presentation of this information in written or tabular form within this section is acceptable. Other sections should be included when appropriate and depending on the review topic (Ex: Pathophysiology; Pharmacokinetics; Clinical Presentation; Diagnosis; Management; Prevention). For an expanded discussion of a well written toxicology case report, please see “Murphy CM: Writing an Effective Review Article. Journal of Medical Toxicology 2012;8:89-90” Specific Reviews: Toxicology Case Files: Section Editor: Jeffrey Suchard, MD Introduction: "Case Files” is a recurring feature of JMT in which Medical Toxicology fellowship programs present clinical cases that highlight important, interesting, and/or controversial issues in the diagnosis and management of poisoned patients. Each “Case Files” article is an extended case report; as the case unfolds, various issues arise, which are discussed in a “question & answer” format that is intended to read like an erudite discussion between a Medical Toxicology fellow and their attending physician. Case Selection: Any case that highlights important, interesting, or controversial issues in the diagnosis and management of poisoned patients could potentially be used as the basis for a “Case Files” article. The cases don’t have to be particularly amazing, like CPC cases often are. In fact, cases involving more common toxins may be preferable, because more commonly-encountered clinical questions can be posed (and discussed), and more published research will be available to use as references. Authorship: Each “Case Files” manuscript will be a co-authored manuscript. The authors will include one Medical Toxicology fellow and one Medical Toxicology attending physician associated with the same fellowship program. Additional authors may occasionally be included, if justification is provided and pre-approval by the Section Editor is granted. The order in which the authors will be listed may be decided by the authors, although it is recommended that the first author be the fellow. Although the discussions within each “Case Files” article are written in a “question & answer” format, it is not necessary that the questions will be written by the fellow and the answers by the attending. Actually, it is expected that both authors will be involved in determining the questions to be asked and in developing the responses to these question, including appropriate references from the literature. Each “Case Files” manuscript will be a co-authored manuscript. The authors will include one Medical Toxicology fellow and one Medical Toxicology attending physician associated with the same fellowship program. Additional authors may occasionally be included, if justification is provided and pre-approval by the Section Editor is granted. The order in which the authors will be listed may be decided by the authors, although it is recommended that the first author be the fellow. Although the discussions within each “Case Files” article are written in a “question & answer” format, it is not necessary that the questions will be written by the fellow and the answers by the attending. Actually, it is expected that both

authors will be involved in determining the questions to be asked and in developing the responses to these question, including appropriate references from the literature. Format for Submission: See (Case files template) for a template of the requested submission format. The overall length of text (excluding title page, tables, figures, and references) should be in the 2500-5000 word range. Editing: Since the opportunity to write a “Case Files” manuscript is by invitation, it is expected that each submitted manuscript will be published. However, the editors reserve the right to reject grossly inadequate submissions and/or require revisions of varying extent. Each submitted (and accepted) manuscript will be edited initially by the Section Editor and returned to the authors for revisions/corrections. Additional editing may occur after the Section Editor has submitted the “finalized” manuscript to the Features Editor. Case files template: [Insert title here]:Case Files of the [Insert fellowship program name here]: [Insert authors here, with affiliations] Corresponding author: [Insert corresponding author info here, including mailing address and email address] Key words: [Insert key words here] CASE PRESENTATION [Insert initial component of case here, in italics. Indent each paragraph.] [Insert first “question” here, in bold. e.g., What are the unique characteristics of suicide attempts by physicians?] [Insert discussion of first question here, normal font. Indent each paragraph.] [Insert second “question” here {assuming there is a second question before the case continues}, in bold.] [Insert discussion of second question here, normal font. Indent each paragraph.] CASE CONTINUATION [Insert additional case details here, in italics. Indent each paragraph.] [Insert additional “question” here, in bold, as above.] [Insert discussion of additional questions here, normal font. Indent each paragraph.] [Additional CASE CONTINUATIONs, and subsequent Q&As, may be inserted as needed.] Toxicology Investigations: Reports of original research studies should follow the "general guidelines" format when applicable and should be between 2500 and 4000 words in length and up to 50 references and 5 figures or tables. A statement of institutional review board (IRB) approval or exemption from full review is required for all research involving human subjects or their data.

Veterinary Toxicology: Veterinary toxicology is a specialty of medicine which deals with the study, diagnosis, treatment and prevention of effects of natural and manmade chemicals, forms of energy, and gasses in animals. Veterinary toxicology also deals with protecting public health by safeguarding human food from chemical residues that are transmitted in the food chain. There is a common thread between medical and veterinary toxicology because toxicants which affect humans also affect animals. Toxicology squarely fits into the “One Health” concept of attaining optimal health for people, animals, and our environment.

The Poison Pen: Manuscripts submitted to The Poison Pen include commentary such as observations and opinions relevant to material appearing in JMT. These should be related to articles published in the previous issue of JMT or relevant to current issues in medical toxicology. These submissions are limited to 500 words, unless permission is obtained from the editor. A maximum of three authors and twelve references are suggested. Letters discussing a JMT article should be received within 12 weeks of the article's publication. Authors of articles about which letters are received will be given the opportunity to reply, which will not be shared with the letter writer prior to publication. Abbreviated case reports are not appropriate as letters. Brief Toxicology Communications: Many aspects of clinical toxicology involve visual clues. The focal point of this section is an image supported by a clinical case or a vignette. This is not intended to replace case reports, which are published elsewhere in the journal. Examples may include a physical finding, creature, plant, chemical structure, medication vial or bottle, ECG tracing, historical photo, etc. The submission should be no greater than 750 words, including the initial vignette and the references. A clinical question should accompany the image. A clinical narrative must be included and will be published separately in the same issue. The narrative should include any pertinent pathophysiology, mechanisms, pharmacokinetics, and reference list. Text and image format must meet the criteria listed on the Instructions for Authors Artwork Guidelines. Images should all be submitted in black and white. Submissions should be sent directly to the managing editor. Preliminary Research: Research Concepts: This section is peer-reviewed and allows expedited review of papers in an attempt to aid in securing extramural funding. For further details, see Bird SB, "Research Concepts, Collaboration, and JMT," JMT 6.1:1-2. Submissions are limited to 5000 words or less Authors must recommend two reviewers with experience as principal investigators of extramurally funded research or NIH scientific reviewers. Submissions require a paragraph describing the NIH or other extramural program announcement or request for application to which the submission responds

JMT Appeals Process for Authors:

General: Authors may request an appeal of publication decisions rendered by an JMT Decision Editor or the Editor-in-Chief. This policy defines the process, once the JMT Editorial office receives the appeal. Qualifying Appeals: Appeals will be considered only if they assert that (1) an error of fact or substantial misunderstanding occurred and/or (2) a disqualifying conflict of interest exists on the part of a reviewer, the Decision Editor or Editor-in-Chief. Appeals Process: All appeals must: (1) be made in writing to the Editor-in-Chief; (2) clearly state the basis for the appeal and provide substantiating information; and (3) be received by the JMT office within 30 days of the date of the letter of rejection. The editorial staff will forward the appeal to the Editor-in-Chief or the Associate Editor within 5 business days. If unavailable, the Editor-in-Chief or Associate Editor may delegate this to another member of the Editorial Board not involved with initial decision. The Editor-in-Chief, the Associate Editor, or their designee will receive the initial and revised (if applicable) manuscripts, all referee reports, and all correspondences relating to the manuscript. The Editor-in-Chief, the Associate Editor, or their designee will choose a disposition within 30 business days of receiving the above materials. The decision may be: (1) to reaffirm the initial decision and take no further action; (2) to overturn the initial decision and accept the manuscript or write a specific revise/reconsider letter; or (3) to decide that additional information is required. If additional information is required, then the manuscript will be sent, with no other background material, to at least two reviewers not associated with the previous review, following usual manuscript review operations/timelines. The Editor-in-Chief, the Associate Editor, or their designee will consider all referee comments at this point to choose final disposition. This decision is final and the author will be notified in writing per usual mechanisms.